Shanghai Hublot Pharmaceuticals Co., Ltd ("Hublot") announced that its China Phase I clinical trial of BW-03, a new siRNA (small interfering nucleic acid) drug for the treatment of Chronic Hepatitis B (CHB), which Hublot developed in-house utilizing its platform technology RADS, will be completed with the first subject dosed on June 27, 2024. （BW-03 is a new siRNA (small interfering nucleic acid) drug for the treatment of chronic hepatitis B (CHB) developed in-house by Hublot using its platform technology RADS. All subjects have been enrolled in the global Phase I clinical trial previously conducted in Australia, Hong Kong, China and Thailand.

For more information, please download the attached document.